The First Molecular-Targeted Agent In Psoriasis Developed In China Is On Its Way
This article was originally published in PharmAsia News
Executive Summary
AKBA, a natural small-molecule agent, is being developed as a new drug for the treatment of psoriasis by a collaboration between University of Ulm in Germany and Shanghai Jiao Tong University